Last updated: April 23, 2026
EP1928449: What the European Patent Office Drug Patent Claims Cover and How They Sit in the European Landscape
What is EP1928449, and what does it protect?
EP1928449 is an EPO-published patent application titled “Lipid vesicles and encapsulated agents” (EPO publication EP 1 928 449 A1). It centers on lipid vesicle (liposome) formulations and the encapsulation of active agents within those vesicles, with claim scope directed to both the vesicle composition and the packaged agent.
Core claim themes (as reflected in the published application’s claim structure):
- Lipid vesicles defined by lipid composition and structural features (e.g., vesicle-type, lipid components used to form bilayers/vesicles).
- Encapsulation of an agent within the vesicle interior and/or associated with the vesicle (depending on claim wording).
- Pharmaceutical use type coverage where the encapsulated agent is used as a drug formulation.
This patent is a formulation-enabling technology rather than a single-molecule small-molecule or monoclonal antibody claim set, so it typically interacts with the landscape through:
- competing or overlapping liposome/nanovesicle formulation patents,
- and downstream product-specific patents (where a marketing authorization is tied to a particular encapsulated drug and a specific lipid system).
What is the claim scope in practice for “drug” products?
EP1928449’s “drug” nature comes from how its claims are drafted: it protects pharmaceutical drug formulations defined by (i) the lipid vesicle system and (ii) the encapsulated agent.
In enforcement terms, claim coverage usually turns on whether a generic or follow-on product can be shown to use:
- a lipid vesicle that matches the claimed composition/structural definitions, and
- an encapsulated agent delivered in the claimed manner (inside vs associated, and under the claimed formulation parameters).
For a product developer, the practical scoping risk is that if their formulation uses substantially the same lipid vesicle architecture and encapsulation mechanism, they may land in the claim zone even if the final drug has differences elsewhere (dose form, manufacturing process details outside the claims, or device aspects).
How broad is the formulation protection (composition vs agent specificity)?
EP1928449 is framed to be reusable across encapsulated actives rather than locked to one active ingredient. That typically means:
- Agent genericity: claims often read on “an agent” as a class term, allowing cover for multiple drugs that can be encapsulated.
- Composition anchors: the strongest limits are usually the lipid vesicle composition definitions and vesicle structural language, which function as the “gate” for infringement.
This creates a dual-layer landscape impact in Europe:
- Upstream: any later liposome-encapsulation patents for specific drugs may face overlap if they use claimed or near-claimed lipid vesicle definitions.
- Downstream: any marketed drug using liposome vesicles may face freedom-to-operate issues if its formulation aligns with EP1928449 claim elements.
What is the timeline and legal context in Europe?
The EPO publication EP 1 928 449 A1 dates to the period when EPO chemical/formulation filings commonly faced later:
- national validation and examination outcomes,
- and EPO opposition proceedings (if filed).
However, a precise enforcement status statement (granted vs lapsed vs opposed in specific countries) requires the legal status per designated contracting states. The published application is what is directly confirmed here; the landscape role in an investment decision still hinges on grant and validity in each state where market entry matters.
What other patents commonly collide with EP1928449 in the EU landscape?
EP1928449 tends to intersect with several adjacent patent families, usually by claim-element overlap:
-
Liposome composition and structure patents
- claims directed at lipid class selection (e.g., phospholipids vs hydrogenated lipids), ratios, and stabilization moieties;
- vesicle size range and lamellarity language.
-
Encapsulation method and loading patents
- process claims can be separate from formulation claims; even if EP1928449 focuses more on the product structure, related families can target manufacturing.
-
Drug-specific liposomal product patents
- these often include the same encapsulation concept but narrow to a specific active and specific lipid system.
-
PEGylated and surface-modified vesicle patents
- claims about stealth coatings, conjugates, or surface functionality can either be additive or carve-outs relative to baseline “lipid vesicle” claims.
From a landscape-mapping standpoint, EP1928449 acts like a platform claim. It is most dangerous for competitors when their product formulation is “close” to the platform’s lipid and encapsulation definitions, because platform claims often have broader reach than product-specific claims.
European Patent Landscape: How to Position EP1928449 vs Competing Formulation Patents
What does the landscape look like around liposomal encapsulation in Europe?
In Europe, liposomal and lipid-encapsulated drug patents cluster in:
- vesicle composition families,
- surface modification families,
- active loading and encapsulation mechanism families,
- and drug-specific delivery families.
EP1928449 sits in the first and third clusters: vesicle composition/definition plus encapsulation of agents.
That matters because:
- A later drug-specific patent can still be invalidated or narrowed if it depends on platform technology that is already claimed elsewhere.
- A later generic or reformulation entrant can still face a product claim infringement risk if their formulation does not sufficiently escape key lipid composition/vesicle/encapsulation limitations.
How do typical EPO claim constructions affect infringement risk?
EPO formulation claim interpretation tends to be literal on:
- defined lipid components,
- defined vesicle structure and composition ranges,
- and defined “agent encapsulation” mechanisms/relationships.
So even if a follow-on product uses a different therapeutic molecule, infringement still often depends on whether the formulation matches the claimed vesicle and packaging features.
Where “agent” is broad, the protected field is larger. Where “agent” is implicitly limited by examples or claim dependencies, effective protection may be narrower in practice.
Key Takeaways
- EP1928449 (EP 1 928 449 A1) is a lipid vesicle formulation patent focused on liposomes and encapsulated agents, with claim scope structured around vesicle composition/definition and encapsulation of an agent.
- Its “drug” impact comes from protecting pharmaceutical formulations, not a single active ingredient. That makes it a platform-style piece in the EU landscape.
- In infringement and FTO work, the dominant scoring elements are usually the lipid vesicle definition and the encapsulation relationship, not just the identity of the therapeutic agent.
- EP1928449 is best treated as a composition/encapsulation risk anchor when mapping adjacent liposomal families across Europe.
FAQs
What type of patent is EP1928449?
A formulation-oriented patent application centered on lipid vesicles (liposomes) and encapsulated agents (delivery vehicle + payload formulation).
Is EP1928449 tied to one specific drug?
The claim structure in the published application is drafted around encapsulated agents in lipid vesicles, so it is not limited to a single molecule in the way a drug-substance patent is.
What product features determine whether a competitor formulation infringes?
The key claim elements are typically the lipid vesicle composition/structure and the way the agent is encapsulated (the claimed relationship of payload to vesicle).
Why does this patent matter for generics or reformulations?
Because platform claims can cover multiple downstream products that share the same underlying vesicle architecture and encapsulation approach, even if the therapeutic use differs.
Does EP1928449 operate like a single-market barrier in Europe?
Its practical impact depends on grant and status across validated states and on how its claim scope aligns with a specific commercial formulation. The published application alone shows the technical scope, not the final enforceability state-by-state.
References
[1] European Patent Office. EP 1 928 449 A1: Lipid vesicles and encapsulated agents. EPO publication database.
